JP2022513162A5 - - Google Patents

Info

Publication number
JP2022513162A5
JP2022513162A5 JP2021531007A JP2021531007A JP2022513162A5 JP 2022513162 A5 JP2022513162 A5 JP 2022513162A5 JP 2021531007 A JP2021531007 A JP 2021531007A JP 2021531007 A JP2021531007 A JP 2021531007A JP 2022513162 A5 JP2022513162 A5 JP 2022513162A5
Authority
JP
Japan
Prior art keywords
subject
composition according
composition
expression level
mds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531007A
Other languages
English (en)
Japanese (ja)
Other versions
JP7650798B2 (ja
JP2022513162A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063372 external-priority patent/WO2020112854A1/en
Publication of JP2022513162A publication Critical patent/JP2022513162A/ja
Publication of JP2022513162A5 publication Critical patent/JP2022513162A5/ja
Priority to JP2022195398A priority Critical patent/JP2023016965A/ja
Priority to JP2024194371A priority patent/JP2025020318A/ja
Application granted granted Critical
Publication of JP7650798B2 publication Critical patent/JP7650798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531007A 2018-11-29 2019-11-26 骨髄異形成症候群を治療する方法 Active JP7650798B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022195398A JP2023016965A (ja) 2018-11-29 2022-12-07 骨髄異形成症候群を治療する方法
JP2024194371A JP2025020318A (ja) 2018-11-29 2024-11-06 骨髄異形成症候群を治療する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862772861P 2018-11-29 2018-11-29
US62/772,861 2018-11-29
US201962811271P 2019-02-27 2019-02-27
US62/811,271 2019-02-27
US201962860557P 2019-06-12 2019-06-12
US62/860,557 2019-06-12
PCT/US2019/063372 WO2020112854A1 (en) 2018-11-29 2019-11-26 Methods of treating myelodysplastic syndrome

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022195398A Division JP2023016965A (ja) 2018-11-29 2022-12-07 骨髄異形成症候群を治療する方法
JP2024194371A Division JP2025020318A (ja) 2018-11-29 2024-11-06 骨髄異形成症候群を治療する方法

Publications (3)

Publication Number Publication Date
JP2022513162A JP2022513162A (ja) 2022-02-07
JP2022513162A5 true JP2022513162A5 (https=) 2022-12-06
JP7650798B2 JP7650798B2 (ja) 2025-03-25

Family

ID=70849825

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531007A Active JP7650798B2 (ja) 2018-11-29 2019-11-26 骨髄異形成症候群を治療する方法
JP2022195398A Pending JP2023016965A (ja) 2018-11-29 2022-12-07 骨髄異形成症候群を治療する方法
JP2024194371A Pending JP2025020318A (ja) 2018-11-29 2024-11-06 骨髄異形成症候群を治療する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022195398A Pending JP2023016965A (ja) 2018-11-29 2022-12-07 骨髄異形成症候群を治療する方法
JP2024194371A Pending JP2025020318A (ja) 2018-11-29 2024-11-06 骨髄異形成症候群を治療する方法

Country Status (15)

Country Link
US (2) US12201645B2 (https=)
EP (1) EP3887537A4 (https=)
JP (3) JP7650798B2 (https=)
KR (2) KR20250074692A (https=)
CN (1) CN113631719A (https=)
AU (2) AU2019389005B2 (https=)
BR (1) BR112021010406A2 (https=)
CA (1) CA3120704A1 (https=)
CL (1) CL2021001386A1 (https=)
IL (1) IL283054A (https=)
MX (1) MX2021006131A (https=)
SG (1) SG11202105573PA (https=)
TW (2) TW202523338A (https=)
UA (1) UA130012C2 (https=)
WO (1) WO2020112854A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL321881A (en) * 2023-01-03 2025-09-01 Geron Corp Methods for treating myelodysplastic syndrome and monitoring treatment
CN116189765B (zh) * 2023-02-23 2023-08-15 上海捷易生物科技有限公司 一种iPS细胞遗传学风险评估系统及应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5523389A (en) 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
CN1317291C (zh) 1999-09-10 2007-05-23 杰龙公司 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用
AU2001227965A1 (en) 2000-01-21 2001-07-31 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2440322C (en) 2001-03-23 2014-09-09 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
DE602004031975D1 (de) 2003-11-04 2011-05-05 Geron Corp Rna-amidate und thioamidateur rnai
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
HRP20171705T1 (hr) 2004-07-02 2017-12-15 Geron Corporation Sinteza zaštićenih 3’-amino-nukleozidnih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
TW200730485A (en) 2005-07-29 2007-08-16 Kalypsys Inc Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
LT2898887T (lt) 2006-10-30 2018-11-12 Geron Corporation Telomerazės inhibitoriaus ir gemcitabino derinys vėžio gydymui
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
EP2134364B1 (en) 2007-03-09 2013-02-13 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
EP3029154B1 (en) 2008-10-17 2017-10-04 Geron Corporation Method for identification of sensitivity of a patient to telomerase inhibition therapy
WO2011017096A2 (en) 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
JP5937520B2 (ja) 2010-02-12 2016-06-22 イプソゲン 骨髄性腫瘍の新規診断マーカーとしてのａｓｘｌ１
US8193484B2 (en) 2010-08-03 2012-06-05 Thermo Finnigan LLP Method and apparatus for automatic estimation of detector gain in a mass spectrometer
AU2012249531B2 (en) * 2011-04-29 2017-06-29 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
MX391121B (es) 2011-10-19 2025-03-19 Pharmacyclics Llc Uso de inhibidores de la tirosina cinasa de bruton (btk).
EP3578563B1 (en) 2011-12-22 2021-04-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
JP6359028B2 (ja) 2012-11-30 2018-07-18 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー
RS59363B1 (sr) 2012-12-07 2019-11-29 Geron Corp Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2014160071A1 (en) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
HUE042792T2 (hu) 2013-11-06 2019-07-29 Mayo Found Medical Education & Res Eljárások és anyagok hematológiai, rosszindulatú betegségek kezelésére
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法

Similar Documents

Publication Publication Date Title
IL272274B2 (en) Antibodies 4h-7b Methods of using them
Trinka et al. Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward
IL272300B2 (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
IL272410B2 (en) Cytokine conjugates for the treatment of autoimmune diseases
BR112015010063B1 (pt) Uso de uma composição compreendendo colchicina, um sal de colchicina ou combinação desses
JP2022525149A5 (https=)
WO2014071231A1 (en) Tec family kinase inhibitor adjuvant therapy
Mentzer Myocardial protection in heart surgery
EP3810095A1 (en) Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
JP7737408B2 (ja) 代謝を緩徐化するための補酵素アンタゴニストの使用
Ding et al. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison
JP2023009229A5 (https=)
JP2020528915A5 (https=)
Cheng et al. Astragaloside IV enhances cardioprotection of remote ischemic conditioning after acute myocardial infarction in rats
IL272163B1 (en) Imetelstat for use in treating myelodysplastic syndrome
JP2022513162A5 (https=)
Han et al. Efficacy and safety of enavogliflozin versus dapagliflozin as add-on to metformin in patients with type 2 diabetes mellitus: a 24-week, double-blind, randomized trial
CN110636841A (zh) 包含苹果酸-天冬氨酸穿梭抑制剂及抗癌剂作为有效成分的癌症预防及治疗用药学组合物
JP7564619B2 (ja) ゴシポールおよびフェンホルミンを有効成分として含む膵臓癌予防および治療用薬学的組成物
Bartoli et al. Bovine model of doxorubicin‐induced cardiomyopathy
CN110996955A (zh) 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
Porter et al. Iron chelation
WO2022213870A1 (zh) 通过口服给药抑制CD4+Treg细胞的药物和方法
JP2016540746A5 (https=)
JP2022518143A (ja) ビタミンｅならびにがん治療用組成物および方法